Last 25 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Compugen Ltd.'s quarterly P/E stands at 0.6x.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 5.29 | 0.64 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.61 | 0.54 | 18.18 | 33.11 | 14.75 | — | — | — | 2.07 | — | — | 126.62 | — |
| — | — | — | — | +613.8% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.84 | 1.41 | 3.14 | 3.31 | 2.36 | 1.54 | 1.60 | 0.88 | 0.80 | 0.71 | 3.44 | 8.46 | 10.62 |
| — | -8.6% | +95.7% | +277.0% | +195.7% | +116.4% | -53.4% | -89.6% | -92.5% | -92.4% | -67.3% | +13.9% | +206.2% | |
| P/FCF | 6.07 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 3.22 | 0.26 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | 3.27 | 0.26 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Compugen Ltd.'s operating margin was 83.2% in Q4 2025, up 500.6 pp QoQ. This marks the 3rd consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of -343.1% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.3% | 94.7% | 12.7% | -32.5% | -5.1% | — | — | — | 87.0% | — | — | 97.0% | — |
| — | — | — | — | -105.8% | — | — | — | — | — | — | — | — | |
| Operating Margin | 43.1% | 83.2% | -417.4% | -670.6% | -367.6% | — | — | — | -47.1% | — | — | -454.5% | — |
| — | — | — | — | -681.2% | — | — | — | — | — | — | — | — | |
| Net Margin | 48.6% | 84.4% | -369.1% | -584.1% | -314.4% | — | — | — | -41.2% | — | — | -428.2% | — |
| — | — | — | — | -662.6% | — | — | — | — | — | — | — | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 44.8% | 77.6% | -14.8% | -13.7% | -13.0% | -17.1% | -14.1% | -12.7% | -3.9% | -12.6% | -7.6% | -6.9% | -6.0% |
| — | +553.6% | -4.9% | -7.6% | -231.5% | -35.7% | -85.2% | -83.4% | +35.1% | -69.2% | +58.6% | +60.0% | +75.0% | |
| ROA | 26.0% | 44.6% | -6.8% | -6.6% | -7.8% | -13.6% | -11.5% | -10.5% | -3.2% | -10.1% | -6.4% | -6.1% | -5.4% |
| — | +427.7% | +40.6% | +36.8% | -145.5% | -34.2% | -79.8% | -72.1% | +40.5% | -62.2% | +49.5% | +48.4% | +70.3% | |
| ROIC | 85.9% | 154.5% | -13.8% | -13.7% | -24.1% | -29.9% | -35.5% | -23.3% | -8.5% | -19.2% | -6.1% | -12.0% | -10.5% |
| — | +617.4% | +61.2% | +41.1% | -183.4% | -55.2% | -485.3% | -93.7% | +18.6% | -123.7% | +82.5% | +74.2% | +84.3% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Compugen Ltd.'s Debt/EBITDA ratio is 0.1x — comfortably within a safe range. The current ratio has improved 12.9% YoY to 6.56x, strengthening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q4 '21 | Q4 '20 | Q3 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.03 | 0.03 | 0.07 | 0.06 | 0.05 | 0.03 | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 | 0.03 | 0.02 |
| — | +8.8% | +160.3% | +128.6% | +95.8% | +6.9% | +0.2% | -2.2% | -0.5% | -3.0% | -72.4% | -82.2% | — | |
| Debt / EBITDA | 0.09 | 0.05 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.56 | 6.56 | 4.38 | 4.74 | 5.09 | 5.81 | 6.43 | 7.13 | 7.23 | 6.16 | 7.21 | 12.27 | 16.93 |
| — | +12.9% | -31.8% | -33.5% | -29.5% | -5.8% | -10.9% | -41.9% | -57.3% | -63.8% | +9.2% | +128.0% | +263.1% | |
| Quick Ratio | 6.56 | 6.56 | 4.38 | 4.74 | 5.09 | 5.81 | 6.43 | 7.13 | 7.23 | 6.16 | 7.21 | 12.27 | 16.93 |
| — | +12.9% | -31.8% | -33.5% | -29.5% | -5.8% | -10.9% | -41.9% | -57.3% | -63.8% | +9.2% | +128.0% | +253.0% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 25 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CGEN stock.
Compugen Ltd.'s current P/E is 5.3x. The average P/E over the last 1 quarters is 0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Compugen Ltd.'s current operating margin is 43.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Compugen Ltd.'s business trajectory between earnings reports.